

- 1 **An evaluation of global Chikungunya clinical management guidelines – a systematic**
- 2 **review**
- 3 Authors:
- 4 Eika Webb, MBBS,¹, ORCID: 0000-0002-6506-3489
- 5 Melina Michelen,* MSc,² ORCID: 0000-0003-3659-7788
- 6 Ishmeala Rigby, * MSc,² ORCID: 0000-0001-9236-7317
- 7 Andrew Dagens, MRCP,² ORCID: 0000-0003-4982-6690
- 8 Dania Dahmash, PhD,² ORCID: 0000-0001-6508-0994
- 9 Vincent Cheng, DPhil,⁴ ORCID:0000-0002-6162-4146
- 10 Reena Joseph, MSc,³ ORCID: 0000-0001-8071-0763
- 11 Samuel Lipworth, MBBS, ^{5,6} ORCID: 0000-0001-5872-9214
- 12 Eli Harriss, BSc,⁷
- 13 Erhui Cai, DPhil,²
- 14 Robert Nartowski, MA²
- 15 Pande Putu Januraga, DrPH,¹² ORCID:0000-0002-2926-0856
- 16 Keerti Gedela, FRCP/MRCP, ³ORCID: 0000-0002-5797-8216
- 17 Evi Sukmaningrum, PhD, ^{10,11} ORCID: 0000-0001-8885-7823
- 18 Helen Groves, PhD⁸ ORCID: 0000-0002-5594-9526
- 19 Peter Hart, PhD⁸ ORCID: 0000-0001-8606-7932
- 20 Tom Fletcher, PhD, ¹ ORCID: 0000-0002-3712-415X
- 21 Lucille Blumberg, MMed⁹ ORCID: 0000-0002-2828-7678
- 22 Peter Horby, FRCP, ² ORCID: 0000-0002-9822-1586
- 23 Shevin T Jacob,** MD MPH¹, ORCID: 0000-0003-2425-9394

24 Louise Sigfrid,** PhD, ² ORCID: 0000-0003-2764-1177

25

26 * Joint second authors

27 **Joint senior authors

28 ¹Liverpool School of Tropical Medicine, Pembroke Pl, Liverpool, UK

29 ² International Severe Acute Respiratory and emerging Infection Consortium, Centre for Tropical

30 Medicine, University of Oxford, Oxford, UK

31 ³ Imperial College London, London, UK

32 ⁴ Bristol Medical School, University of Bristol, Bristol, UK

33 ⁵ Oxford University Hospitals NHS Foundation Trust, Oxford, UK

34 ⁶ Nuffield Department of Medicine, University of Oxford, Oxford, UK

35 ⁷ Bodleian Health Care Libraries, University of Oxford, Oxford, UK

36 ⁸ Wellcome Trust, 183 Euston Rd, London, UK

37 ⁹ National Institute for Communicable Diseases, South Africa

38 ¹⁰ Atma Jaya Catholic University of Indonesia, Indonesia

39 ¹¹ HIV AIDS Research Centre-HPSI, AJCU

40 ¹² Udayana University, Bali, Indonesia

41 **Abstract**

42 **Background:** Chikungunya virus (CHIKV) has expanded its geographical reach in recent decades and is
43 an emerging global health threat. CHIKV can cause significant morbidity and lead to chronic, debilitating
44 arthritis in up to 40% of infected individuals, impacting on livelihoods. Prevention, early identification,
45 and clinical management are key for improving outcomes. This review aims to evaluate the availability of
46 inclusive, evidence-based clinical management guidelines for CHIKV in a global context.

47
48 **Methods:** Six databases were searched systematically from inception to 14th October 2021 and
49 complemented with a grey literature search until 16th September 2021. We included CMGs providing
50 supportive care and treatment recommendations. Two reviewers independently screened records,
51 extracted data and assessed quality using the AGREE II tool. Findings are presented in a narrative
52 synthesis.

53
54 **Results:** Twenty-eight CMGs were included; most were of low-quality (median score 2 out of 7 (range
55 1-7)). None were produced specifically in a low-income country and 54% (15/28) were produced more
56 than five years ago. There were variations in the CMGs' guidance on the management of different at-risk
57 populations, long-term sequelae, and the prevention of disease transmission in community and hospital
58 settings. In the acute phase, 54% (15/28) recommended hospitalisation for severe cases, however only
59 39% (11/28) provided clinical management guidance for severe disease. Further, 46% (13/28) advocated
60 for steroids in the chronic phase, yet 18% (5/28) advised against its use.

61
62 **Conclusion:** There was a lack of high-quality CMGs that provided supportive care and treatment
63 guidance; this scarcity may impact patient care and outcomes. It is essential that existing guidelines are
64 updated and adapted to provide detailed evidence-based treatment guidelines for different at-risk
65 populations. This study also highlights a need for more research into the management of the acute and
66 chronic phases of CHIKV infection to inform evidence-based care.

67

68 **Systematic review registration:** PROSPERO CRD42020167361

69 **Keywords:** Clinical management guidelines, AGREE II, Supportive care, Chikungunya, Emerging
70 infections,

71

72 **What was known before**

73 • CHIKV is endemic across most of the southern hemisphere, with risk of expansion into new
74 regions driven by global travel, trade, and climate change.

75

76 • Infection can result in severe illness with long-term sequelae, particularly in vulnerable groups.
77 Chronic sequelae of CHIKV infection is a cause of significant debilitating morbidity affecting
78 individual functionality and quality of life with wider health system and socio-economic impact.

79

80 • There is no effective vaccine or targeted treatment against Chikungunya and supportive care is
81 the mainstay of treatment.

82

83 • Even with a limited evidence base, clinical management guidelines (CMGs) are key tools for
84 standardising best available evidence-based care, and reduce inappropriate use of treatments, to
85 reduce morbidity and improve patient outcomes.

86

87 **What this study adds**

88 • This review highlights a global scarcity of CMGs for chikungunya providing detailed guidance
89 on optimal supportive care and treatment for different at-risk populations and settings.

90

- 91 • There was limited guidance available on care for severe cases, and available guidance was
92 heterogenous and discordant (e.g., on use of analgesia, corticosteroids, and monitoring).
93
- 94 • The limited availability of up-to-date CMGs and heterogenous recommendations identified is a
95 concern, which may impact on equity in access to best available evidence-based care and patient
96 outcomes.
97
- 98 • Further research into access to and implementation of CMGs in different settings is needed, to
99 ensure equitable access to best available care.
100
- 101 • This study also highlights a need for further investment into research into supportive care and
102 treatment for different at-risk populations, and new evidence incorporated into guidelines to
103 reduce morbidity and improve long term outcomes for the people affected by and at risk of
104 Chikungunya.
105
106
107
108
109
110
111
112
113
114
115

116 INTRODUCTION

117 Chikungunya is a disease caused by the chikungunya virus (CHIKV); an arthropod-borne virus
118 transmitted to humans primarily by *Aedes* mosquitoes. Since its description in 1952, CHIKV has caused
119 millions of human infections in Africa, the Indian Ocean islands, Asia, Europe, and the Americas.¹ A
120 major outbreak in 2004 affected more than 100 countries with over 10 million cases and this was followed
121 by another large outbreak in 2013 in the Americas.² Multiple factors have contributed to these outbreaks
122 including a lack of vaccines and effective treatments, limited mosquito control in densely populated urban
123 areas, and climate changes.³ It is estimated that 1.3 billion people live in areas at risk of CHIKV
124 infection.^{4,5} Modelling studies of climate change, indicate that regions such as Europe are at risk of
125 introduction of CHIKV in the future.^{4,6,7} The recent and projected expansion in geographical range and
126 risk of travel-imported infections, with risk of local outbreaks during favourable transmission conditions
127 have increased CHIKV's recognition as an emerging global health threat.

128
129 Chikungunya has a wide spectrum of clinical presentations, which can be classified into three phases
130 (acute, sub-acute and chronic).⁸ Acute CHIKV (classed as less than three weeks post onset of symptoms)
131 manifests as a febrile illness with predominant symptoms of polyarthralgia, rash, and headache. This can
132 be followed by a subacute phase lasting up to three months.⁹ An estimated 40% of people are affected by
133 long-term chronic sequelae defined as persistent symptoms more than 3 months post-onset, for up to 6
134 years.^{9,10} The chronic manifestations of CHIKV include debilitating symptoms of chronic arthralgia,
135 arthritis, fatigue which may lead to disability and diminished quality of life,¹¹ with severe impact on an
136 individual's ability to work. Although the acute infection is self-limiting and rarely life-threatening, it can
137 result in severe illness and mortality particularly in neonates, older adults (over 65 years) and people with
138 comorbidities.^{2,8,12-14} To date, there is no specific treatment approved for acute or chronic chikungunya
139 illness; although vaccines have been developed and tested in humans, none are yet available.^{15,16} Thus, to
140 improve patient outcomes, and reduce the chronic burden; supportive care is essential for the clinical
141 management of chikungunya.¹⁷

142 Parallels can be drawn between CHIKV, and SARS-CoV-2 given that both viruses can cause acute illness
143 followed by long-term sequelae in survivors, which can have a devastating impact on individuals'
144 psychological and physical health and capacity to return to work. Accordingly, public health
145 interventions adopted by many countries to slow the spread of COVID-19 (i.e., reduction in the number
146 of regular household surveys; diversion of resources towards the COVID-19 response; lockdowns) may
147 likely have had a negative impact on vector surveillance and control.^{18,19} As we are transitioning out of
148 the pandemic, we need to prepare to shift resources to identify and mitigate the wider pandemic
149 consequences and strengthen our capacity to respond to future epidemics.

150
151 CHIKV infection is a serious global public health problem, predominantly affecting populations and
152 health systems in lower resourced settings, and with risk of importation into new, naïve regions. The aim
153 of this review is to explore the availability and accessibility of evidence-based clinical management
154 guidelines for chikungunya globally and evaluate their quality and harmonisation of treatment
155 recommendations.

156

157 **METHODS**

158 We conducted a systematic review of chikungunya CMGs using Cochrane systematic review
159 methodologies,²⁰ structured according to the Preferred Reporting Items for Systematic Reviews and Meta-
160 Analyses (PRISMA) statement (supplementary file).²¹ The protocol is registered with the International
161 Prospective Register of Systematic Reviews (PROSPERO) (CRD42020167361).²²

162

163 **Search strategy**

164 We conducted an electronic database search for chikungunya CMGs using Ovid Medline, Ovid Embase,
165 Ovid Global Health, Scopus, Web of Science Core Collection and WHO Global Index Medicus from
166 inception to 14th October 2021. Search strategies applied the Canadian Agency for Drugs and
167 Technologies in Health (CADTH) database guidelines search filter (supplementary file 1).²³ Further

168 CMGs were identified through an extensive systematic grey literature search up to 16th September 2021.
169 We searched Google and Google Scholar using predefined keywords in main languages including Arabic,
170 English, French, German, Mandarin, Russian, and Spanish. We also contacted clinician members of the
171 global International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) network
172 requesting CMGs.²⁴

173

174 **Eligibility criteria**

175 We included chikungunya CMGs that provided treatment and/or supportive care recommendations. There
176 was no language limitations We excluded CMGs that were pure diagnostics, animal, or public health
177 guidelines. Only the most recent version of any CMG was included.

178

179 **Screening and data extraction**

180 Search results were screened independently by two reviewers using the Rayan systematic review
181 software.²⁵ CMGs were screened first by title and abstract, then by full text. Screening, data extraction
182 and critical appraisal were completed by two reviewers. Data was extracted by one reviewer using a
183 standardised form and validated by a second reviewer (supplementary file). We extracted data on
184 bibliography, issuing organisations, populations covered, supportive care and treatment recommendations
185 for the acute and chronic disease (supplementary file). Disagreements were resolved via consensus or by a
186 third reviewer. Non-English language CMGs were screened, and data was translated using Google
187 translate and screened and data extracted by reviewers with good to excellent knowledge of the language.

188

189 **Quality appraisal**

190 Quality was independently assessed by two reviewers using the Appraisal of Guidelines for Research and
191 Evaluation II (AGREE II) Instrument.²⁶ This tool provides an objective framework which aims to assess
192 the guideline development process and quality. It is a 23-item tool that spans six domains comprising
193 different aspects of the CMG: 1) scope and purpose; 2) stakeholder involvement; 3) rigour of

194 development; 4) clarity of presentation; 5) applicability and 6) editorial independence. Each domain has
195 several sub-criteria which are scored to assess whether the criteria are met using a seven-point Likert
196 scale, from 1 (strongly disagree) to 7 (strongly agree). A score of 100% is achieved if a CMG scores 7 for
197 all items in the domain and 0% if each reviewer scored 1 for all domain items. The final domain score
198 was calculated as the average score by the different reviewers, as per the AGREE-II tool's user manual.²⁶
199 When there was limited information about the methodology presented in the CMG, efforts were made to
200 search for additional information via associated webpages.

201
202 CMGs were considered of high quality if they scored more than 60% in three or more domains, including
203 domain three (rigour of development), which is considered a high-quality indicator; moderate quality if
204 they scored more than 60% in three or more domains but not in domain three and low quality if they did
205 not reach these criteria. As per AGREE-II methodology, individual CMGs were also given an overall
206 quality assessment score, which was informed by the domain scores, ranging from one to seven (high-
207 quality score ≥ 6 ; medium-quality score 4-5; low-quality score ≤ 3), together with a recommendation for
208 use with or without further modifications.²⁶ CMGs with a total overall quality score of 1 were not
209 recommended for use, total overall scores of 2-5 were recommended for use with modifications and 6-7
210 recommended for use without modifications.

211 212 **Data analysis**

213 We conducted a narrative synthesis of the quality, availability, scope, and inclusivity of the CMGs. The
214 availability of CMGs was assessed by whether open-sourced CMGs could be identified and were
215 stratified by origin: (1) international and regional organisations (e.g., WHO; PAHO); (2) national
216 organisations (e.g., Ministries of Health) and (3) clinical reference websites (e.g., Medscape, UptoDate).
217 We assessed inclusivity based on inclusion of recommendations for traditionally more vulnerable at-risk
218 groups, including infants/children, pregnant women, older people, and people living with HIV or

219 comorbidities that may render them at higher risk of severe disease. The ggplot2 library and Tableau
220 software were used to produce graphics.^{27,28}

221

222 **Patient public involvement**

223 There was no patient or public involvement due to the ongoing pandemic restrictions.

224

225 **RESULTS**

226 From 2981 records screened, twenty-eight CMGs met the inclusion criteria (Figure 1).^{9,29-54}

227

228 **Figure 1: PRISMA diagram**

229

230 **Characteristics of included CMGs**

231 Half of the CMGs were in English (50%, 14/28);^{9,30-32,34,36,37,42,44-47,52,54} 43% (12/28) in Spanish^{29,35,38-}
232 ^{41,43,48-50,53,55} and 7% (2/28) in Portuguese.^{33,51} Most were produced by National Health Organisations
233 (61%, 17/28), and 46% (13/28)^{32-34,36,37,39,44-46,51-54} published in the last 5 years (Table 1).

234

235 **Availability**

236 Half of the CMGs were produced in Latin Americas (50%, 14/28),^{29,33,35,38,40,41,43,48-51,53-55} 14% in Europe
237 (4/28),^{9,30,31,39} 14% in Asia (4/28),^{37,42,44,45} 11% in North America (3/28)^{32,34,36} and 11% by global
238 organisations (3/28)^{32,34,52} (Figure 2). Most were produced by organisations in high- or upper-middle
239 income countries (61%, 17/28),^{33,35,38,40,41,48,49,51,54,55} followed by lower-middle-income countries (18%,
240 5/28).^{29,37,43-45} None were produced in a low-income country. (World Bank) (Table 1). Sixty-four percent
241 (18/28) of CMGs were produced in countries where Chikungunya is endemic.

242

243

244

245 **Figure 2: Chikungunya outbreaks (1999-2020) and geographic distribution of identified CMGs**

246

247 **Quality**

248 The overall quality of the CMGs ranged from one to seven (median: 2 out of 7) (Table 2). Most (86%,
249 24/28) were of low quality (score ≤ 3), two of median (scores 4-5) and two of high quality (score 6-7).

250 The higher scoring CMGs were produced by Mexico Ministerio De Salud, UpToDate, World Health
251 Organisation Southeast Asia and República Dominicana Ministerio de Salud Pública. Although
252 UpToDate produces CMGs for unspecified settings, these are only accessible upon subscriptions. No
253 freely accessible, global, high-quality CMG was identified within our study. The highest scoring domains
254 were clarity of presentation [median (IQR): 61% (58-72)] and scope and purpose [median (IQR): 56%
255 (43-70)]. The lowest scoring domain was editorial independence [median (IQR): 15% (0-35)]. Similarly,
256 the domains for rigour of development [median (IQR): 28% (21-45)], applicability [median (IQR): 29%
257 (16-40)] and stakeholder involvement [median (IQR): 36.1 (2-63)] scored low. Broad variation in scores
258 were seen in the domains for ‘editorial independence’ and ‘rigour of development’ especially (Table 1
259 and Figure 3).

260

261

262 **Table 1 AGREE II scores**

263 The table present the results of the assessment of each Chikungunya clinical management guidelines
264 using the AGREE II scores by domain and the overall quality.

265

CMG	Year	Scope and purpose (%)	Stakeholder involvement (%)	Rigour of development (%)	Clarity of presentation (%)	Applicability (%)	Editorial Independence (%)	Overall quality (1-7)
ACCAR	2018	61.1	36.1	44.8	55.6	20.8	41.7	1

BCDC	2017	19.4	11.1	13.5	61.1	12.5	16.7	2
BMS	2015	47.2	27.8	18.8	72.2	27.1	16.7	1
BSR	2017	44.4	22.2	51	69.4	10.4	45.8	2
BZLMS	2017	55.6	30.6	28.1	58.3	45.8	0	1
CDC	2020	8.3	25	7.3	58.3	12.5	0	1
CMS	2018	69.4	19.4	24	69.4	39.6	0	2
CRMS	2014	47.2	30.6	8.3	50	50	0	1
DRMSP	2014	83.3	41.7	35.4	61.1	62.5	0	4
EMS	2014	58.3	30.6	20.8	66.7	52.1	0	2
ESMS	2014	77.8	38.9	26	69.4	29.2	12.5	3
GMS	2015	69.4	50	16.7	58.3	16.7	0	2
IMOH	2016	16.7	5.6	9.4	58.3	12.5	16.7	1
JIMA	2020	52.8	38.9	40.6	58.3	8.3	95.8	2
MMS	2015	94.4	63.9	93.8	91.7	62.5	87.5	7
MS	2019	8.3	44.4	36.5	58.3	4.2	41.7	1
PAHO	2011	52.8	47.2	22.9	52.8	31.3	25	1
PHE	2014	2.8	2.8	0	27.8	4.2	0	1
PMS	2015	80.6	44.4	36.5	83.3	29.2	0	3
PMSP	2015	75	44.4	27.1	47.2	41.7	0	2
PRMS	2014	27.8	13.9	27.1	72.2	31.3	0	2
PUK	2014	38.9	36.1	46.9	44.4	6.3	66.7	2
RSMBT	2020	55.6	33.3	22.9	24	72.2	22.9	2
SMOH	2016	72.2	38.9	31.3	63.9	29.2	0	3
SPILF	2015	55.6	38.9	45.8	61.1	16.7	33.3	2
UTD	2020	47.2	44.4	85.4	80.6	35.4	91.7	6
WHO	2017	69.4	33.3	43.8	55.6	37.5	25	2
WHOSEA	2008	80.6	61.1	52.1	88.9	22.9	0	4

Median	-	55.6	36.1	27.6	61.1	28.1	14.6	2
Range	-	(8-94)	(2-63)	(0-93)	(27-91)	(4-62)	(0-87)	(0-7)

266

267 **Abbreviations:** ACCAR: Pan-American League of Associations for Rheumatology-Central American Caribbean
 268 and Andean Rheumatology Association, BCDC: Bangladesh Centre for Disease Control, BMS: Bolivia Ministerio
 269 De Salud, BSR: Brazilian Society of Rheumatology, BZLMS: Brasil Ministério da Saúde, CDC: Centers for Disease
 270 Control and Prevention, CMS: Chile Ministerio De Salud, CRMS: Costa Rica Ministerio De Salud , DRMSP:
 271 República Dominicana Ministerio de Salud Pública, EMS: Ecuador Ministerio De Salud, ESMS: El Salvador
 272 Ministerio De Salud, GMS: Guatemala Ministerio De Salud, IMOH: India Ministry of Health, JIMA: Journal of
 273 Indian Medical Association. MMS: Mexico Ministerio De Salud, MS: Medscape, PAHO: Pan American Health
 274 Organisation, PHE: Public Health England, PMS: Peru Ministerio De Salud, PMSP: Paraguay Ministerio de Salud,
 275 PRMS: Puerto Rico Ministerio De Salud, PUK: Patient UK, RSMBT: Revista da Sociedade Brasileira de Medicine
 276 Tropical, SMOH: Spain Ministry of Health, SPILF: Société de Pathologie Infectieuse de Langue Française, UTD:
 277 UptoDate, WHO: World Health Organisation, WHOSEA: World Health Organisation Southeast Asia, CMG: Clinical
 278 management guidelines, AGREE- Appraisal of guidelines for research and evaluation

279

280

281

282 **Figure 3 AGREE II domain scores**

283

284 **Inclusivity**

285 Most CMGs (89%, 25/28)^{9,29,31-35,37-42,44-53,55} mentioned vulnerable groups including children (75%,
 286 21/28),^{9,29,31,32,37-43,45,46,48-51,53,55} pregnant women (68%, 19/28),^{9,29,32,33,35,38-45,47-49,51,52,52,53} people aged >65
 287 years (96% 27/28),^{9,29,31-55} people living with HIV (21%, 6/28)^{29,38,40,41,49,55} and people living with
 288 comorbidities (61%, 17/28).^{9,29,31,32,34,36-38,40,41,43,44,48-51,54} Many (61% (17/28))^{30,31,33-37,41,42,44,45,45-47,53-55,55,55}
 289 provided some guidance for all of these groups; however, recommendations varied in their level of detail
 290 with only a minority giving specific supportive care guidance for pregnant women and children.

291

292

293 **Scope**

294 All CMGs gave recommendations for the management of acute and chronic manifestations of
295 chikungunya, although the level of detail varied (Table 2 and 3). There was considerable variation
296 between CMGs in the recommendations for the management of patients with long-term sequelae and for
297 different at-risk populations. Further, there were differences in the guidance addressing preventive
298 measures of disease transmission both in the community and in hospital settings.

299

300 ***Acute Phase***

301 Half of the CMGs (50%, 14/28)^{9,29,37,40,41,43,45-47,51-55} stated that there was no efficacious antiviral treatment
302 available for CHIKV and most (96%, 27/28) that management should be symptom-driven.^{29-38,40-55,55}
303 Many (68%, 19/28)^{29,32,33,35,37,38,40-45,47-53} provided guidance on management of the acute phase, with
304 administration at different health facility levels depending on disease severity: outpatient care (home
305 based and at the primary care level), secondary level (district hospitals) and at the tertiary level (referral
306 hospitals). The principles of outpatient management were generally consistent amongst the CMGs with
307 recommendations including rest (39%, 11/28),^{32,32,33,36,38,40,46-48,52,53,55} hydration (43%, 12/28),^{29,31-33,36-}
308 ^{38,41,46,52,53,55} cold compresses (11%, 3/28),^{38,45,51} antihistamines (39%, 11/28)^{32,38,40,42,44,45,49,53-55} and
309 analgesia (96% 27/28). A minority (25%, 4/12)^{29,37,38,52,53} advised the need to assess the patient's
310 hydration status to assess whether intravenous fluid was required, one (8%, 1/12)⁵³ advised suspending
311 diuretics.

312

313 Fifty-four percent of CMGs (15/28)^{33,35,37,38,40-45,47-49,51,52} recommended hospitalisation for severe cases;
314 however, only a minority (39%, 11/28)^{9,29,33,34,37,38,41,46,51,52,54} gave guidance regarding the clinical
315 management of severe cases. The CMGs (54%, 15/28)^{33,35,37,38,40-45,47-49,51,52} providing guidance regarding
316 hospitalisation criteria gave several indications including: any signs of haemodynamic instability (46%,
317 13/28),^{33,35,38,41-45,47-49,51,52} or atypical chikungunya (36%, 10/28),^{29,33,35,38,41,43,47-49,52} severe pain
318 unresponsive to analgesia (25%, 7/28),^{35,37,38,41,42,44,45} signs of haemorrhage (46%, 13/28)^{29,33,35,38,41-45,47-49}

319 and signs of decompensation from underlying comorbidities (25%, 7/28).^{29,33,35,38,43,47,49} Supportive care
320 recommendations included use of intravenous fluids to treat shock (55%, 6/11),^{29,37,45,45,47,48,52}
321 haemodynamic monitoring (55%, 6/11),^{29,33,34,45-47} blood components (18%, 2/11),^{37,45} intensive care
322 support as required (9%, 1/11)⁹ and immunoglobulins in chikungunya-related polyneuropathy (4%, 1/28).

323

324 *Antimalarials*

325 None of the CMGs advocated for use of empiric antimalarials, despite some CMGs (10%, 2/21)^{9,44}
326 advising malaria should be considered in the differential diagnosis. However, CMGs did discuss the use
327 of antimalarial chloroquine derivatives for the treatment of chronic manifestations (24%, 4/17).^{33,37,44,45}

328

329 *Analgesia*

330 All CMGs recommended some form of analgesia with 75% (21/28)^{29,31-33,35,37,40-48,52-55,55} recommending
331 paracetamol as first line treatment for pain and its antipyretic properties. Some (36%, 10/28)^{9,33,35,40,47,48,52-}
332 ⁵⁵ advised escalating to opiates, tramadol, or codeine alone or in combination with paracetamol, for
333 uncontrolled pain. Two (7%, 2/28)^{33,51} recommended dipyron for mild pain. There was wide and
334 contradictory advice given regarding non-steroidal anti-inflammatory drugs (NSAIDs) in the acute phase.
335 Half (54%, 15/28) advised considering the use of NSAIDs.^{29,31,32,34,36-42,44,47,48,55} However, 75% (21/28)
336 advised avoiding salicylates in adults during the acute phase due to risk of haemorrhage,^{9,29,32-35,37-44,47-53}
337 and 40% (11/28) advised against NSAIDs,^{9,33,35,43,45,46,49,51-54} while one CMG stated that NSAIDs should
338 not be avoided, citing a lack of evidence.³² Some (29%, 8/28)^{9,29,35,41,46,48-50} recommended excluding co-
339 infection with dengue prior to NSAID administration.

340

341 *Corticosteroids*

342 The recommendations for corticosteroids were also heterogenous. A third (36%, 10/28)^{32,35,41,44,46-48,50,53,54}
343 advised a short course of corticosteroids if not responding to analgesia. A number of indications were
344 given for corticosteroid, including severe joint pain refractory to NSAIDs or other analgesia (80%,

345 8/10),^{32,35,41,44,46–48,53} highly inflammatory forms (30%, 3/10);^{32,53,54} disabling arthritis (40%, 4/10)^{32,41,44,54}
346 or when contraindications against NSAIDs (10%, 1/10).⁵³ Prednisolone was most recommended (50%,
347 5/10),^{32,41,46,53,54} with CMGs advising adult dosage ranging from 10mg to 20mg per day (60%, 3/5) based
348 on clinical judgment,^{32,46,53} escalating to 0.5mg/kg/day (80%, 4/5)^{32,41,53,54} for severe cases. Four CMGs
349 (80%, 4/5)^{32,41,53,54} gave corticosteroid duration advise, ranging, from 5 days (60%, 3/5)^{32,41,53} with a
350 weaning period of 10 days to 1-2 months for severe cases (40%, 2/5)^{32,54} with a correspondingly longer
351 weaning period. In contrast, two CMGs (40%, 2/5) stated that the duration of corticosteroid use should
352 not exceed one month,^{32,53} with one citing the SPILF guideline.⁹ Although the majority (80%, 4/5)^{32,41,53,54}
353 advised on the need for tapering steroid doses, only one CMG gave a justification, stating that there was a
354 risk of rebound symptoms if abruptly withdrawn.⁵⁴ The remaining CMGs (50%, 5/10) did not specify
355 corticosteroid dose or type.^{35,44,47,48,50} In contrast to these recommendations, 43%
356 (12/28)^{9,29,34,37,38,40,43,45,49,51,52,55} advised against the use of steroids in the acute phase. Only a minority gave
357 justifications for avoidance, stating either a lack of evidence (8%, 1/12),³⁴ lack of short-or long-term
358 benefit regardless of form of administration (8%, 1/12)⁵² or a risk of rebound symptoms (8%, 1/12).⁵⁵
359 Furthermore, one CMG [cite] had contradictory recommendations within its guideline, advising the use of
360 short-term corticosteroids for individuals with refractory pain in the acute phase, while also advising
361 against the use of systemic corticosteroids in the acute phase.²⁹
362
363 A minority of CMGs (14%, 4/28)^{29,32,33,54} also indicated the use of steroids in the subacute phase to treat
364 symptoms refractory to NSAIDs, moderate pain and for arthritis/tenosynovitis. Three of these CMGs
365 (75%, 3/4)^{32,33,54} advised that prednisolone was first-line, and that steroids use should be limited to one
366 month. One CMG (25%, 1/4)³³ provided recommendations on how to assess improvement (ability to walk
367 without assistance; satisfactory pain control) to guide dose and duration.

368

369

370

371 **Table 2 Summary of CMG treatment recommendations in the acute phase**

372 The table presents an overview of the main treatments recommended in the acute phase in each guideline,

373 and if a treatment was recommended to use, not recommended or if no advice was provided.

374 R= recommended. RA= recommended to avoid. NS= not stated.

375 *Indicated in subacute CHIKV

376

Guidelines	Region	Year	Acute interventions					
			Paracetamol	NSAIDs	Opioids	Antihistamines	Antimalarials	Steroids
ACCAR	Global	2018	R	RA	RA	NS	NS	R
BCDC	Asia	2017	R	RA	R	R	NS	RA
BMS	Latin America	2015	R	R	NS	NS	NS	RA*
BSR	Latin America	2017	R	RA	R	NS	NS	RA
BZLMS	Latin America	2017	R	RA	R	NS	NS	R*
CDC	North America	2020	NS	R	NS	NS	NS	NS
CMS	Latin America	2018	R	RA	R	R	NS	R
CRMS	Latin America	2014	R	RA	R	NS	NS	R
DRMSP	Latin America	2014	R	R	NS	R	NS	RA
EMS	Latin America	2014	R	R	R	NS	NS	R

ESMS	Latin America	2014	R	RA	R	NS	NS	RA
GMS	Latin America	2015	R	R	NS	R	NS	RA
IMOH	Asia	2016	R	R	R	R	NS	R
JMA	Asia	2020	R	R	NS	R	NS	RA
MMS	Latin America	2015	R	RA	NS	R	NS	RA
MS	North America	2019	NS	R	NS	NS	NS	RA
PAHO	Latin America	2011	NS	R	R	NS	NS	R
PHE	Europe	2014	NS	NS	NS	NS	NS	NS
PMS	Latin America	2015	R	R	NS	R	NS	RA
PMSP	Latin America	2015	R	R	R	NS	NS	R
PRMS	Latin America	2014	R	NS	R	NS	NS	R
PUK	Europe	2014	R	R	NS	NS	NS	NS
RSMBT	Latin America	2020	R	RA	R	NS	NS	R*
SMOH	Europe	2016	R	R*	R	NS	NS	NS
SPILF	Europe	2015	NS	RA	NR	NS	NS	RA
UTD	Global	2020	R	R	R	NS	NS	R*
WHO	Global	2017	R	RA	R	NS	NS	RA
WHOSEA	Asia	2008	R	R	NS	R	NS	NS

Total Recommended (R) % (n/n)	82% (23/28)	54% (15/28)	54% (15/28)	32% (9/28)	0% (0/28)	46% (13/28)
Total Not Recommended (R) % (n/n)	0% (0/28)	39% (11/28)	4% (1/28)	0% (0/28)	0% (0/28)	43% (12/28)

377
378
379 **Abbreviations** : NSAID: Non-steroidal Anti-inflammatory Drugs, *WHOSEA* World Health Organisation Southeast
380 Asia, *PAHO* Pan American Health Organisation, *EMS* Ecuador Ministerio De Salud, *ESMS* El Salvador Ministerio
381 De Salud, *PHE* Public Health England, *PRMS* Puerto Rico Ministerio De Salud, *DRMSP* República Dominicana
382 Ministerio de Salud Pública, *CRMS* Costa Rica Ministerio De Salud, *PUK* Patient UK, *BMS* Bolivia Ministerio De
383 Salud, *GMS* Guatemala Ministerio De Salud, *PMS* Peru Ministerio De Salud, *SPILF* Société de Pathologie
384 Infectieuse de Langue Française, *MMS* Mexico Ministerio De Salud, *PMSP* Paraguay Ministerio de Salud, *SMOH*
385 Spain Ministry of Health, *IMOH* India Ministry of Health, *BSR* Brazilian Society of Rheumatology, *WHO*
386 WorldHealth Organisation, *BZLMS* Brasil Ministério da Saúde, *BCDC* Bangladesh Centre for Disease Control, *CMS*
387 Chile Ministerio De Salud, *ACCAR* Pan-American League of Associations for Rheumatology-Central American
388 Caribbean and Andean Rheumatology Association, *MS* Medscape, *CDC* Centers for Disease Control and Prevention,
389 *RSMBT* Revista da Sociedade Brasileira de Medicina Tropical, *UTD* UptoDate, *JIMA* Journal of Indian Medical
390 Association.

391
392
393 **Chronic Phase**
394 Most CMGs (93%, 26/28)^{9,29,32-55} addressed the management of long-term sequelae, based on the
395 principles of managing more common inflammatory arthropathies such as rheumatoid arthritis (RA). The
396 recommendations included analgesia, corticosteroids, disease modifying anti-rheumatic drugs (DMARDs)
397 and antimalarial chloroquine derivatives. Some CMGs (18%, 5/28)^{9,33,42,51,54} advised using quantitative
398 scoring measures (visual scales, clinical scores and structured questionnaires) to measure outcomes such
399 as pain, joint involvement, quality of life and functional capacity in adults. The most common scale
400 recommended to assess severity and to monitor the efficacy of treatment was a visual analogue scale

401 (VAS) (80%, 4/5).^{9,33,51,54} Other scales recommended were Routine Assessment of Patient Index Data 3
402 (RAPID3), Disease Activity Score-28 (DAS28) and Douleur Neuropathique 4 (DN4) to assess the
403 functional impact of pain and level of neuropathic pain, respectively.^{9,54}

404

405 *Analgesia*

406 Most CMGs (86%, 24/28)^{9,29-33,35,36,39-44,46-54} advised managing chronic pain using analgesia, primarily
407 NSAIDs (75%, 18/24),^{9,29,32,33,35,41-44,46-50,50-52,54} paracetamol (45%, 11/24)^{9,31-33,35,39,40,42,49,52,54} and opiates
408 (21%, 5/24).^{9,33,51,52,54} A minority (13%, 3/24)^{51,53,54} gave guidance regarding the duration of treatment
409 which ranged from reassessing after four,⁵¹ eight⁵⁴ to several weeks.⁵³ The rest (92%, 22/24) lacked
410 clarity regarding the length of time analgesia should be continued.^{9,29,29-33,35,36,38,39,39-44,46-49,49,50,50,52}

411

412

413

414 *Corticosteroids*

415 Almost half the CMGs (46%, 13/28) advised giving steroids in the chronic phase.^{29,32,36,37,39,41-44,47,51,52} The
416 most common indication given for administration of corticosteroids was disabling peripheral arthritis
417 refractory to other treatments (62%, 8/13),^{29,33,36,39,41,44,47,52} followed by neuropathic symptoms (8%,
418 1/13).⁵¹ Moreover, to those who experience arthralgia, arthritis, tendinitis, or bursitis with evidence of
419 severe synovitis, joint swelling and persistent elevation of inflammatory markers (8%, 1/13).³² Most
420 recommended prednisolone (31%, 4/13),^{32,33,41,51} most (75%, 3/4) specifying a dosage of
421 0.5mg/kg/day.^{32,33,41} There was considerable variation in the recommendations regarding duration, with
422 CMGs advising courses of five,³² ten,⁴¹ 21,³³ or 28 days.³⁷ One CMG (8%) advised using 5 to 20 mg/day
423 prednisone for musculoskeletal and neuropathic symptoms for 6 to 8 weeks with a weaning period to
424 avoid symptom recurrence.⁵¹ For administration, although most CMGs advised oral steroids (31%,
425 4/13),^{33,37,39,51} a few advised that local intra-articular injections could be used (15%, 2/13).^{39,47} A minority
426 of CMGs (18%, 5/28)^{9,34,38,49,55} advised against the use of corticosteroids in the chronic phase giving

427 reasons such as the risk of rebound symptoms (20%, 1/5)⁵⁵ and lack of published evidence (20%, 1/5).³⁴

428 The rest of the CMGs did not give a justification for avoidance (60%, 3/5).^{9,38,49}

429

430 *DMARDs*

431 Over half of the CMGs (61%, 17/28)^{9,29,32,33,37,39,41,43-48,51-54} gave guidance on the use of DMARDs in the

432 chronic phase; yet there was variation on which DMARD was first line. Methotrexate was recommended

433 as first line therapy by most (65%, 11/17);^{9,29,32,39,41,43,46-48,52,53} whereas others (24%, 4/17) recommended

434 chloroquine/ hydroxychloroquine.^{33,44,44,45} One (6%, 1/17) recommended that methotrexate should be used

435 for inflammatory joint disease (moderate or severe disease affecting >5 joints) and hydroxychloroquine

436 reserved for less severe forms.⁵⁴ Another (6%, 1/17) noted that there was a lack of data comparing the

437 efficacy of methotrexate and hydroxychloroquine, but recommended hydroxychloroquine as it the safer

438 choice for its anti-inflammatory and possible antiviral effects.³³ Two CMGs (12%, 2/17) recommended

439 methotrexate either in combination with another DMARD, such as sulfasalazine or chloroquine.^{46,51} One

440 CMG (6%, 1/17) divided chronic manifestations into post-chikungunya rheumatoid arthritis

441 (methotrexate first line), post-chikungunya spondyloarthritis (NSAIDs first line) and post-chikungunya

442 undifferentiated polyarthritis (NSAIDs first line; corticosteroids second line).⁹ Five CMGs (18%)

443 provided guidance for neuropathic pain management of using amitriptyline, pregabalin, gabapentin and

444 carbamazepine.^{9,33,45,51,54}

445

446 **Table 3 Summary of CMG recommendations for treatment of chronic sequelae**

447 The table presents an overview of the main treatments recommended in the chronic phase in each

448 guideline, and if a treatment was recommended to use, not recommended or if no advice was provided.

449 R= recommended. RA= recommended to avoid. NS= not stated.

450

451

Guidelines	Region	Year	Chronic interventions					
			Analgesia			Steroids	DMARDs	
			Paracetamol	NSAIDs	Opioids		MTX	HCQ
ACCAR	Global	2018	NS	R	NS	NS	R	R
BCDC	Asia	2017	NS	NS	NS	NS	NS	R
BMS	Latin America	2015	NS	R	NS	R	R	NS
BSR	Latin America	2017	NS	R	R	R	R	R
BZLMS	Latin America	2017	R	R	R	R	NS	R
CDC	North America	2018	NS	R	NS	R	NS	NS
CMS	Latin America	2018	R	R	R	NS	R	NS
CRMS	Latin America	2014	R	R	NS	R	NS	NS
DRMSP	Latin America	2014	NS	NS	NS	RA	NS	NS
EMS	Latin America	2014	NS	R	NS	R	R	NS
ESMS	Latin America	2014	NS	R	NS	R	R	NS

GMS	Latin America	2015	NS	NS	NS	RA	NS	NS
IMOH	Asia	2016	NS	R	NS	NS	NS	R
JIMA	Asia	2020	NS	NS	NS	R	NS	R
MMS	Latin America	2015	R	R	NS	RA	NS	NS
MS	North America	2019	NS	NS	NS	RA	NS	NS
PAHO	Latin America	2011	NS	R	NS	R	R	RA
PHE	Europe	2014	NS	NS	NS	NS	NS	NS
PMS	Latin America	2015	R	NS	NS	NS	NS	NS
PMSP	Latin America	2015	NS	R	NS	R	R	NS
PRMS	Latin America	2014	NS	R	NS	NS	NS	NS
PUK	Europe	2014	R	NS	NS	NS	NS	NS
RSMBT	Latin America	2020	R	R	R	NS	R	R
SMOH	Europe	2016	R	NS	NS	R	R	NS
SPILF	Europe	2015	R	R	R	RA	R	NS
UTD	Global	2020	R	R	NS	R	R	RA
WHO	Global	2017	R	R	R	NS	R	NS
WHOSEA	Asia	2008	R	R	NS	R	NS	NS
Total Recommended (R) % (n/N)			39% (11/28)	64% (18/28)	18% (5/28)	46% (13/28)	65% (11/17)	41% (7/17)

Total Not Recommended (R) % (n/N)	0% (0/28)	0% (0/28)	0% (0/28)	18% (5/28)	0% (0/28)	7% (2/28)
--------------------------------------	-----------	-----------	-----------	------------	-----------	-----------

452
 453 **Abbreviations:** NSAID: Non-steroidal Anti-inflammatory Drugs, DMARD: Disease-modifying Antirheumatic
 454 Drugs; MTX: Methotrexate; HCQ: Hydroxychloroquine; *WHOSEA* World Health Organisation Southeast Asia,
 455 *PAHO* Pan American Health Organisation, *EMS* Ecuador Ministerio De Salud, *ESMS* El Salvador Ministerio De
 456 Salud, *PHE* Public Health England, *PRMS* Puerto Rico Ministerio De Salud, *DRMSP* República Dominicana
 457 Ministerio de Salud Pública, *CRMS* Costa Rica Ministerio De Salud, *PUK* Patient UK, *BMS* Bolivia Ministerio De
 458 Salud, *GMS* Guatemala Ministerio De Salud, *PMS* Peru Ministerio De Salud, *SPILF* Société de Pathologie
 459 Infectieuse de Langue Française, *MMS* Mexico Ministerio De Salud, *PMSP* Paraguay Ministerio de Salud, *SMOH*
 460 Spain Ministry of Health, *IMOH* India Ministry of Health, *BSR* Brazilian Society of Rheumatology, *WHO* World
 461 Health Organisation, *BZLMS* Brasil Ministério da Saúde, *BCDC* Bangladesh Centre for Disease Control, *CMS* Chile
 462 Ministerio De Salud, *ACCAR* Pan-American League of Associations for Rheumatology-Central American
 463 Caribbean and Andean Rheumatology Association, *CDC* Centers for Disease Control and Prevention, *MS*
 464 Medscape, *RSMBT* Revista da Sociedade Brasileira de Medicina Tropical, *UTD* UptoDate, *JIMA* Journal of Indian
 465 Medical Association.

466
 467 ***Vulnerable populations***

468 *Pregnant women*
 469 Most (75%, 21/28) addressed management during pregnancy.^{9,29,31–33,35,36,38–45,47–49,51–53} Yet, limited CMGs
 470 (29%, 6/21)^{9,38,41,43,52,53} gave guidance on CHIKV symptom control during pregnancy, advising to use
 471 paracetamol (67%, 4/6).^{9,38,52,53} Moreover, to consider amoxicillin in febrile (>38.5C) women (17%, 1/6)⁹
 472 and to avoid NSAIDs and aspirin (50%, 3/6)^{9,52,53} due to the risks of closure of the ductus arteriosus, fetal
 473 renal failure and risk of intrauterine death [cite]. Some CMGs (57%, 12/21) recommended referral to
 474 health services for monitoring of mother and child, but the advice varied.^{9,29,35,38,40,40–42,47–49,51,52} One (8%,
 475 1/12)³⁵ recommended admitting all pregnant women with suspected chikungunya if in the last trimester;

476 whereas one (8%, 1/12) specified from 38 weeks.⁴⁸ In contrast, two CMGs (16%, 2/12)^{33,49}
477 recommended daily monitoring of pregnant women with suspected chikungunya; three (25%, 3/12)
478 recommended obstetric referral if in the final trimester.^{9,52,53} Delaying delivery beyond the highly
479 viraemic stage to try to prevent mother-to-child transmission (MTCT) was advised in four (33%, 4/12).
480 One (8%, 1/12)⁹ advising use of tocolytics, one (8%, 1/12)³⁵ postponement of elective caesarean section.
481 Further, four CMGs (19%, 4/21) advised that caesarean sections did not prevent mother-to-child
482 transmission (MTCT).^{9,38,45,49}

483

484 *Children*

485 Most CMGs (79%, 22/28) identified children and neonates as having a higher risk of developing severe
486 CHIKV infection and advised hospital referral, but their criteria varied.^{9,29,31,33,35,37–40,40–55} Four (18%,
487 4/22)^{9,41,52,53} advised inpatient monitoring for signs of infection of neonates born to mothers with
488 suspected chikungunya for seven days. The guidance changed for neonates born to mothers with
489 confirmed infection, with three CMGs (14%, 3/22) advising that inpatient monitoring should be five days,
490 ^{9,52,53} one at least seven days.⁴¹ One (5%, 1/22) recommended that symptomatic neonates should be
491 managed in the neonatal intensive care unit.³⁸ Four (18%, 4/22) addressed breastfeeding, stating there was
492 no risk of transmission through breastmilk.^{38,44,45,47} Four CMGs (18%, 4/22) advised infants at risk of
493 CHIKV infection younger than 12 months to be admitted to hospital for observation.^{29,37,40,45} Four (18%,
494 4/22) advised children under two years old to be followed up daily in a primary care facility during the
495 acute phase [cite]. Nine CMGs (32%) specified the risk of Reye's syndrome associated with aspirin use in
496 children younger than 12 years old [cite]. Four (18%, 4/22)^{9,29,52,53} advised against NSAID administration
497 in children under the age of 3 months, and three (11%) against codeine use in children younger than 12
498 years.^{9,52,53} One CMG (4%) advised against use of dipyron in infants younger than three months or
499 weighing less than 5kg.⁵⁴

500

501

502 *Older adults and those with comorbidities*

503 Although 96% (27/28) of CMGs^{9,29,30,32,34–51,53–56} included advice for older adults (CMGs generally
504 defined as those aged over 60 or 65 years) and those with comorbidities, this advice was limited in scope.
505 Two (22%, 2/9) stated that people over 60 years old had a 50-times higher mortality risk compared to
506 younger adults.^{41,43} While 81% (22/27)^{9,29,31,32,35–39,41,42,44,46–53,55} advised that older adults were at increased
507 risk of severe/atypical disease and death, only seven (26%, 7/27)^{37,41,41,42,45,48,53} recommended referral to
508 hospital for monitoring. One CMG (11%, 1/9) stated that in people over 65 years old CHIKV infection
509 could cause complications and lead to dementia, paralysis and kidney disease.⁴⁴ Over half of the CMGs
510 (61%, 17/28)^{9,29,31,32,34,36,38,40,43,44,48–52,54} advised that people with chronic conditions such as diabetes,
511 hypertension or heart disease were at higher risk of developing severe/ atypical disease or deterioration
512 due to decompensation of their pre-existing condition. Of these, nine (81%, 9/11) suggested having a
513 lower threshold for hospital referral, and three close monitoring of these patients, and adult over 65 years
514 old. In keeping with general guidance, five CMGs (45%, 5/11) advised prescribing NSAIDs with caution
515 in patients with comorbidities due to risk of renal impairment and bleeding risk.^{33,38,40,48,54}

516

517 ***Prevention of onward transmission***

518 Most CMGs (71%, 20/28)^{9,29,31,32,35,37,38,40–51,53} gave advice regarding prevention of transmission.
519 Recommendations included the use of mosquito repellents (50%, 10/20),^{9,31,35,40,41,43,44,47,50,51} protective
520 clothing (35%, 7/20),^{31,40,41,43,50,51} mosquito nets (60%, 12/20),^{9,37,40–44,47,49–51,53} and isolation (25%, 5/20)
521 of the patient and those in proximity to the patient. It was recommended to continue these measures
522 throughout the febrile phase of illness to reduce risk of transmission. In contrast, two CMGs stated that
523 there was no requirement to segregate the infected patient in a household.^{44,45} Only three CMGs (15%,
524 3/20) advised on the risk of blood-borne transmission^{9,38,46} with one specifying highest risk within the first
525 five days of symptomatic infection.³⁸ Two (10%, 2/20) highlighted risk of transmission via organ/tissue
526 transplantation.^{38,46} Seven CMGs (35%)^{9,29,44,45,48,50,51} recommended vector control measures around the

527 hospital/homes of infected patients, using insecticides,^{9,48} fumigation²⁹ and eradication of breeding
528 sites.^{9,50} Some (65%, 13/20) advised informing public health authorities.^{29,31,31,35,40–42,44,45,47,48,48–50}

529

530 **Discussion**

531 This review highlights the limited availability of high-quality CMGs for chikungunya globally. In the
532 CMGs identified there were heterogenous recommendations on supportive care and treatments. Although
533 there was a consensus in the guidelines on the symptomatic treatment for acute non-severe illness, there
534 was a general lack of detailed supportive care guidance regarding patients with acute severe disease.
535 Furthermore, there were significant differences in the guidance around corticosteroids, with certain CMGs
536 advocating for their use in the acute phase, while a third advised that the acute phase was a
537 contraindication. The duration of steroid treatment for both acute and chronic disease was another point of
538 contention between the CMGs. The evidence base around corticosteroid use in acute illness is uncertain
539 with studies limited in size and a scarcity of RCTs investigating corticosteroid use in acute CHIKV.

540

541 The evidence base around corticosteroid use in acute CHIKV is uncertain. One prospective randomized
542 parallel group study of 120 patients with acute CHIKV in South India demonstrated that the addition of
543 corticosteroid to NSAIDs reduced pain and improved quality of life and advocated for combination
544 treatment in acute illness.⁵⁷ Another small study of 19 cases observed an improvement in mobility with
545 short term corticosteroids in acute CHIKV, however noted that there was a risk of rebound symptoms
546 after treatment cessation.⁵⁸ Several reviews advised against the use of corticosteroids citing risks such as
547 rebound symptoms and immunosuppression causing potential disease exacerbation.^{59,60} It can be
548 reasonably assumed that the clinical guidelines are contradictory and lack clarity due to a scarcity of
549 research into the use of corticosteroids in acute chikungunya infection.

550

551 The joint pain caused by CHIKV infection may be debilitating, which can limit even the simplest daily
552 activities. Polyarthralgia is recurrent in 30 to 40% of infected individuals and may persist for years.⁶¹

553 Furthermore, CHIKV infection can lead to death either through the infection and its associated
554 complications or by triggering a decompensation in patients with pre-existing co-morbidities.⁶² The risk
555 of prolonged sequelae in populations in lower resourced settings especially can have a profound impact
556 on livelihoods, with a wider socio-economic impact on individuals, their families and the wider society.
557 Considering the high number of people affected and at risk of CHIKV infection, the scarcity and
558 heterogeneity as well as the sometimes contradictory treatment recommendations in the CMGs available
559 for chikungunya are reasons for concern.

560

561 Most CMGs included guidance on the treatment for pregnant women and children and there was general
562 consensus that this group were at higher risk of severe infection. Yet, guidance regarding symptomatic
563 treatment was limited and there were variations in the guidance around referral criteria to health services.
564 Moreover, there were wide variations in risk and need for monitoring of infection in young children, and
565 in the treatment recommendations and duration. Furthermore, only a minority of CMGs mentioned
566 potential factors to mitigate the risks of MTCT during delivery. For children, although many CMGs
567 identified that they were a high-risk group, only a minority gave guidance on hospitalisation criteria and
568 advised on symptom control. The CMGs were also limited in specific advice for older people and for
569 those with co-morbidities, both of whom are at higher risk of more severe disease. Given the substantial
570 risk CHIKV infection presents to neonates, the lack of clear guidance around reducing MTCT is a
571 concern. Although there are novel approaches to prevent the risk of MTCT, such as anti-CHIKV
572 hyperimmunoglobulins, there is currently no approved treatment^{63–65} and published studies are scarce.

573

574 Furthermore, there was considerable variation in the guidance for treating and managing long-term
575 chronic, often debilitating, sequelae. The evidence into effective treatments is limited, and symptomatic
576 treatment without appropriate individual follow-up, whilst crucial to the quality of life of many patients,
577 has not been found to have an effect in diminishing mortality.⁶⁶ A systematic review of five RCTs with

578 small sample sizes found that the evidence on treatments was insufficient from a safety or efficacy point
579 of view.⁶⁷

580
581 Although most CMGs provided recommendations for post-acute follow-up care and treatment of chronic
582 complications, the recommendations were heterogenous and with limited evidence provided to support
583 them. There was variation in the recommendations of DMARDs for the management of chronic
584 chikungunya, particularly between hydroxychloroquine and methotrexate. One study examined
585 combination DMARD therapy versus hydroxychloroquine treatment in 72 patients with post-chikungunya
586 arthritis and found that a combination of DMARDs were superior to hydroxychloroquine monotherapy
587 treatment with improvements in disability, reduction in pain and disease activity.⁶⁸ Despite
588 acknowledging this lack of benefit, however four CMGs recommended hydroxychloroquine as a first line
589 DMARD.^{33,37,44,45} Existing interventional clinical research studies are limited in size as highlighted in
590 Martí-Carvajal et al., with a lack of standardised methodologies, the ability to conduct meta-analyses is
591 restricted, thus limiting our evidence base in determining the most effective therapies for treating chronic
592 manifestations of CHIKV infection.⁶⁷ The paucity of clear guidance is a disservice to patients, particularly
593 given that most patients developing acute severe illness and complications fall within vulnerable groups.
594 Our data highlights a need for robust RCTs with adequate statistical power to identify best supportive care
595 and new treatments to improve short and long term CHIKV outcomes.

596
597 This review is not without limitations. Despite a systematic search, additional local guidelines not retrieved
598 by our searches may exist. Approximately half of the included CMGs were in a language other than English,
599 and although these were assessed by a reviewer with good knowledge of that language, there may have
600 been slight nuances lost in translation. Furthermore, the AGREE-II tool²⁶ assess methodological aspects
601 relevant to guideline development, but not the validity of the clinical management recommendations
602 themselves. Whilst many of the CMGs scored poorly in the rigour of development domain, conclusions
603 about the validity of the clinical guidance made can therefore not be derived from these scores.²⁶ Despite

604 these limitations, this review identifies concerning gaps and disparities within the CMGs. Firstly, there is
605 an issue of accessibility with the two highest quality CMGs identified in this review not being freely
606 available. One is only available via paid subscription⁶⁹ and the other a national guideline in Spanish.⁴⁹
607 Developing CMGs is resource intensive, and for infectious diseases with rapidly changing epidemiology,
608 requires systems for regular reviews of the literature, updating and re-dissemination. CHIKV
609 disproportionately impacts on lower resourced settings, where such resources may not be readily available.
610 Further, other infections may take priority when there is international pressure and/or funding to develop
611 research and guidelines (e.g., SARS-CoV-2, HIV, malaria). International high-quality CMGs can fill this
612 gap, if they are readily accessible, and can easily be adapted and adopted by local settings during outbreaks.
613 This may also help ensure there are resources available to incorporate new evidence and disseminated this
614 via international platforms. The WHO new living Covid-19 review is an example of this.

615

616 **Conclusion**

617 There is a lack of high-quality CMGs detailing supportive care guidance in chikungunya globally,
618 particularly for those at risk of severe illness. Given the risks that CHIKV infection pose globally and in
619 particular to vulnerable groups such as children, individuals older than 65 years and those with co-
620 morbidities, it is essential that existing guidelines are updated and adapted to include recommendations
621 for people with severe illness. Chikungunya is an illness predominantly affecting populations in lower-
622 resourced settings, with profound impact on quality of life and livelihoods. Further research is needed into
623 effective treatments and vaccines, to generate evidence to inform high quality CMGs and improve patient
624 and epidemic outcomes. Investment in a 'living review' framework, for international CMGs that can be
625 readily adopted by local settings is recommended to improve access to inclusive, up to date, evidence-
626 based treatment guidelines.

627

628

629 **Author's contributions**

630 AD, VC, LS, SL, EH, STJ, EW, MM, IR developed the study protocol. EH, AD carried out the database
631 search with input from MM, EW and IR. EW, MM, IR, AD, EC conducted the grey literature search.
632 EW, RJ, AD, MM screened articles for inclusion. AD, EW, IR, RJ, MM extracted the data and completed
633 the risk of bias analysis. EW, MM, RJ, SL, and IR led on data analysis and presentation of the results. All
634 co-authors informed the interpretation of the findings. EW led on writing the manuscript with inputs from
635 LS, IR, MM, DD, RN, PPJ, ES and KG. LS, PH, TF, LB and STJ provided overall supervision,
636 leadership and advice. PH, HG, STJ, TF, PWH, LS, AD, and LB conceptualised the project. All authors
637 reviewed and approved the final version of the manuscript.

638

639 **Acknowledgements**

640 Thanks to the ISARIC Global Support Centre for logistical and administrative support, especially to Sarah
641 Moore and Romans Matulevics for invaluable support for this project.

642

643 **Funding statement**

644 This work was supported by the UK Foreign, Commonwealth and Development Office, Wellcome Trust
645 [215091/Z/18/Z], the Bill & Melinda Gates Foundation [OPP1209135]. For the purpose of Open Access,
646 the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising
647 from this submission.

648

649 **Competing interests**

650 All authors have completed the ICMJE uniform disclosure form and declare: no support from any
651 organisation for the submitted work; no financial relationships with any organisations that might have an
652 interest in the submitted work in the previous three years.

653

654 **Ethical approval**

655 Not required

656

657 **Data sharing**

658 All of the data is presented in the manuscript and supplementary material.

659

660 **Transparency statement**

661 The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate,
662 and transparent account of the study being reported; that no important aspects of the study have
663 been omitted; and that any discrepancies from the study as originally planned and registered have
664 been explained.

665 **List of abbreviations:**

667 CHIKV- Chikungunya Virus

668 CMG- Clinical Management Guideline

669 DMARD- Disease Modifying Anti-Rheumatic Drug

670 PAHO- Pan American Health Organisation

671 WHO- World Health Organisation

672 AGREE-Appraisal of Guidelines for Research and Evaluation II

673 PROSPERO-The International Prospective Register of Systematic Reviews

674 SARS-CoV-2- severe acute respiratory syndrome coronavirus 2

675 COVID-19-Coronavirus Disease

676 PRISMA-Preferred Reporting Items for Systematic Reviews and Meta-Analyses

677 CADTH-Canadian Agency for Drugs and Technologies in Health

678 ISARIC- International Severe Acute Respiratory and Emerging Infection Consortium

- 679 WHO-World Health Organisation
- 680 PAHO-Pan American Health Organisation
- 681 HIV-Human Immunodeficiency Virus
- 682 IQR-Interquartile range
- 683 WHOSEA-World Health Organisation Southeast Asia
- 684 ACCAR-Pan-American League of Associations for Rheumatology-Central American Caribbean and
- 685 Andean Rheumatology Association
- 686 BCDC-Bangladesh Centre for Disease Control
- 687 BMS-Bolivia Ministerio De Salud
- 688 BSR-Brazilian Society of Rheumatology
- 689 BZLMS-Brasil Ministério da Saúde
- 690 CDC-Centers for Disease Control and Prevention
- 691 CMS-Chile Ministerio De Salud
- 692 CRMS-Costa Rica Ministerio De Salud
- 693 DRMSP-República Dominicana Ministerio de Salud Pública
- 694 EMS-Ecuador Ministerio De Salud
- 695 ESMS-El Salvador Ministerio De Salud
- 696 GMS-Guatemala Ministerio De Salud
- 697 IMOH-India Ministry of Health
- 698 JIMA-Journal of Indian Medical Association
- 699 MMS-Mexico Ministerio De Salud
- 700 MS-Medscape
- 701 PHE-Public Health England
- 702 PMS-Peru Ministerio De Salud
- 703 PMSP-Paraguay Ministerio de Salud
- 704 PRMS-Puerto Rico *Ministerio* De Salud

- 705 PUK-Patient UK
- 706 RSMBT-Revista da Sociedade Brasileira de Medicina Tropical
- 707 SMOH-Spain Ministry of Health
- 708 SPLIF-Société de Pathologie Infectieuse de Langue Française
- 709 UTD-UptoDate
- 710 NSAIDs-Non-Steroidal Anti-inflammatory Drugs
- 711 RAPID3-Routine Assessment of Patient Index Data 3
- 712 DAS28-Disease Activity Score-28
- 713 DN4-Douleur Neuropathique 4
- 714 DMARD- Disease Modifying Anti-rheumatic Drugs
- 715 MTCT-mother-to-child transmission
- 716 RCT-Randomised Control Trial
- 717 MTX-Methotrexate
- 718 HCQ-Hydroxychloroquine
- 719 R-Recommended
- 720 NS- Not Stated
- 721 RA- Recommended to avoid

722

723 **References**

- 724 1. Rodrigues Faria N, Lourenço J, Marques de Cerqueira E, Maia de Lima M, Pybus O, Carlos Junior
- 725 Alcantara L. Epidemiology of Chikungunya Virus in Bahia, Brazil, 2014-2015. PLoS Curr. 2016
- 726 Feb 1;8:ecurrents.outbreaks.c97507e3e48efb946401755d468c28b2.

- 727 2. Suhrbier A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat
- 728 Rev Rheumatol. 2019 Oct;15(10):597–611.

- 729 3. Gould EA, Higgs S. Impact of climate change and other factors on emerging arbovirus diseases.
730 Trans R Soc Trop Med Hyg. 2009 Feb;103(2):109–21.
- 731 4. Tjaden NB, Suk JE, Fischer D, Thomas SM, Beierkuhnlein C, Semenza JC. Modelling the effects of
732 global climate change on Chikungunya transmission in the 21st century. Sci Rep. 2017 Jun
733 19;7(1):3813.
- 734 5. Nsoesie EO, Kraemer MU, Golding N, Pigott DM, Brady OJ, Moyes CL, et al. Global distribution
735 and environmental suitability for chikungunya virus, 1952 to 2015. Eurosurveillance. 2016 May
736 19;21(20):30234.
- 737 6. Leta S, Beyene TJ, De Clercq EM, Amenu K, Kraemer MUG, Revie CW. Global risk mapping for
738 major diseases transmitted by *Aedes aegypti* and *Aedes albopictus*. Int J Infect Dis IJID Off Publ Int
739 Soc Infect Dis. 2018 Feb;67:25–35.
- 740 7. Projected change in the climatic suitability for Chikungunya transmission — European Environment
741 Agency [Internet]. [cited 2022 Feb 16]. Available from: [https://www.eea.europa.eu/data-and-](https://www.eea.europa.eu/data-and-maps/figures/projected-change-in-the-climatic)
742 [maps/figures/projected-change-in-the-climatic](https://www.eea.europa.eu/data-and-maps/figures/projected-change-in-the-climatic)
- 743 8. Cunha RV da, Trinta KS. Chikungunya virus: clinical aspects and treatment - A Review. Mem Inst
744 Oswaldo Cruz. 2017 Aug;112(8):523–31.
- 745 9. Simon F, Javelle E, Cabie A, Bouquillard E, Troisgros O, Gentile G, et al. French guidelines for the
746 management of chikungunya (acute and persistent presentations). November 2014. Med Mal Infect.
747 2015 Jul;45(7):243–63.
- 748 10. Sissoko D, Malvy D, Ezzedine K, Renault P, Moschetti F, Ledrans M, et al. Post-Epidemic
749 Chikungunya Disease on Reunion Island: Course of Rheumatic Manifestations and Associated
750 Factors over a 15-Month Period. PLoS Negl Trop Dis. 2009 Mar 10;3(3):e389.

- 751 11. Soumahoro M-K, Boelle P-Y, Gaüzere B-A, Atsou K, Pelat C, Lambert B, et al. The Chikungunya
752 Epidemic on La Réunion Island in 2005–2006: A Cost-of-Illness Study. *PLoS Negl Trop Dis*. 2011
753 Jun 14;5(6):e1197.
- 754 12. Bower H, Karsany M el, Adam AAAH, Idriss MI, Alzain MA, Alfakiyousif MEA, et al.
755 “Kankasha” in Kassala: A prospective observational cohort study of the clinical characteristics,
756 epidemiology, genetic origin, and chronic impact of the 2018 epidemic of Chikungunya virus
757 infection in Kassala, Sudan. *PLoS Negl Trop Dis*. 2021 Apr 30;15(4):e0009387.
- 758 13. Dorléans F, Hoen B, Najioullah F, Herrmann-Storck C, Schepers KM, Abel S, et al. Outbreak of
759 Chikungunya in the French Caribbean Islands of Martinique and Guadeloupe: Findings from a
760 Hospital-Based Surveillance System (2013-2015). *Am J Trop Med Hyg*. 2018 Jun;98(6):1819–25.
- 761 14. Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann O, Quenel P, et al. Atypical
762 Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease
763 during the 2005-2006 outbreak on Réunion. *Epidemiol Infect*. 2009 Apr;137(4):534–41.
- 764 15. Reisinger EC, Tschismarov R, Beubler E, Wiedermann U, Firbas C, Loebermann M, et al.
765 Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-
766 CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. *Lancet*
767 *Lond Engl*. 2019 Dec 22;392(10165):2718–27.
- 768 16. Folegatti PM, Harrison K, Preciado-Llanes L, Lopez FR, Bittaye M, Kim YC, et al. A single dose of
769 ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a
770 phase 1 clinical trial. *Nat Commun*. 2021 Jul 30;12(1):4636.
- 771 17. Zaid A, Gérardin P, Taylor A, Mostafavi H, Malvy D, Mahalingam S. Chikungunya Arthritis:
772 Implications of Acute and Chronic Inflammation Mechanisms on Disease Management. *Arthritis*
773 *Rheumatol Hoboken NJ*. 2018 Apr;70(4):484–95.

- 774 18. Seelig F, Bezerra H, Cameron M, Hii J, Hiscox A, Irish S, et al. The COVID-19 pandemic should
775 not derail global vector control efforts. *PLoS Negl Trop Dis*. 2020 Aug 31;14(8):e0008606.
- 776 19. Wilder-Smith A, Tissera H, Ooi EE, Coloma J, Scott TW, Gubler DJ. Preventing Dengue
777 Epidemics during the COVID-19 Pandemic. *Am J Trop Med Hyg*. 2020 Aug;103(2):570–1.
- 778 20. Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, et al. Cochrane Rapid
779 Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. *J Clin*
780 *Epidemiol*. 2021 Feb;130:13–22.
- 781 21. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic
782 Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Med*. 2009 Jul 21;6(7):e1000097.
- 783 22. Andrew Dagens, Peter Horby, Shevin Jacobs, Lucille Blumberg, Jonathan Sterne, Henry Kyobe-
784 Basa, Tom Fletcher, Louise Sigfrid. A systematic review of the availability, quality and inclusivity
785 of supportive care guidelines in the management of high consequence infectious disease [Internet].
786 [cited 2021 Dec 21]. Available from:
787 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=167361&VersionID=1302745
- 788 23. Canadian Agency for Drugs and Technologies in Health. Strings attached: CADTH database search
789 filters [Internet]. 2021 [cited 2022 Feb 17]. Available from: [https://www.cadth.ca/strings-attached-](https://www.cadth.ca/strings-attached-cadths-database-search-filters#:~:text=When%20using%20the%20CADTH%20search,Ottawa%3A%20CADTH%3B%20)
790 [cadths-database-search-](https://www.cadth.ca/strings-attached-cadths-database-search-filters#:~:text=When%20using%20the%20CADTH%20search,Ottawa%3A%20CADTH%3B%20)
791 [filters#:~:text=When%20using%20the%20CADTH%20search,Ottawa%3A%20CADTH%3B%20](https://www.cadth.ca/strings-attached-cadths-database-search-filters#:~:text=When%20using%20the%20CADTH%20search,Ottawa%3A%20CADTH%3B%20)
792 [021.](https://www.cadth.ca/strings-attached-cadths-database-search-filters#:~:text=When%20using%20the%20CADTH%20search,Ottawa%3A%20CADTH%3B%20)
- 793 24. International Severe Acute Respiratory and emerging Infection Consortium [Internet]. ISARIC.
794 [cited 2022 Feb 16]. Available from: <https://isaric.org/>

- 795 25. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for
796 systematic reviews. *Syst Rev*. 2016 Dec;5(1):210.
- 797 26. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II:
798 advancing guideline development, reporting and evaluation in health care. *Can Med Assoc J*. 2010
799 Dec 14;182(18):E839–42.
- 800 27. Wickham H. *ggplot2: Elegant Graphics for Data Analysis* [Internet]. Springer-Verl N Y [Internet].
801 2016; Available from: <https://ggplot2.tidyverse.org>
- 802 28. Tableau (version. 9.1). *J Med Libr Assoc JMLA*. 2016 Apr;104(2):182–3.
- 803 29. Nava AC, Barba CAP, Mendoza AC, Velasco . Omar Flores, Benavides RR, Pérez CGR. Bolivian
804 Ministry of Health and Sports - Dengue, Zika and Chikungunya Surveillance and Control Area
805 [Internet]. MINISTERIO DE SALUD; 2015 [cited 2021 Dec 10]. Available from:
806 <https://www.minsalud.gob.bo/38-libros-y-normas/fichas-bibliograficas/1574-area-dengue>
- 807 30. Public Health England. Chikungunya [Internet]. The characteristics, symptoms, diagnosis and
808 epidemiology of chikungunya. 2014 [cited 2021 Dec 10]. Available from:
809 <https://www.gov.uk/guidance/chikungunya>
- 810 31. Harding M, Willacy H. Chikungunya Fever; Chikungunya Virus information. *Patient* [Internet].
811 2015 [cited 2021 Dec 10]. Available from: <https://patient.info/doctor/chikungunya-fever-pro>
- 812 32. Miner Jonathan; Lenschow Deborah; Wilson Mary. Chikungunya fever: Treatment and prevention
813 [Internet]. 2020. Available from: [https://www.uptodate.com/contents/chikungunya-fever-treatment-](https://www.uptodate.com/contents/chikungunya-fever-treatment-and-prevention)
814 [and-prevention](https://www.uptodate.com/contents/chikungunya-fever-treatment-and-prevention)
- 815 33. Brazil Ministry of Health. Chikungunya Manejo Clínico [Internet]. [cited 2022 Feb 17]. Available
816 from: https://bvsmis.saude.gov.br/bvs/publicacoes/chikungunya_manejo_clinico.pdf

- 817 34. Natesan SK, Chandrasekar PH. Chikungunya Virus Workup: Approach Considerations, Serological
818 Testing, Viral Culture [Internet]. 2019 [cited 2021 Dec 10]. Available from:
819 <https://emedicine.medscape.com/article/2225687-workup>
- 820 35. Salud CRM de, Social CC de S. Chikungunya. Protocolo de vigilancia y manejo clínico. 2014 Jul
821 [cited 2021 Dec 6]; Available from: <http://repositorio.binasss.sa.cr/xmlui/handle/20.500.11764/3719>
- 822 36. Clinical Evaluation & Disease | Chikungunya virus | CDC [Internet]. Centres for Disease Control
823 and Prevention. 2018 [cited 2021 Dec 10]. Available from:
824 <https://www.cdc.gov/chikungunya/hc/clinicalevaluation.html>
- 825 37. Journal of Indian Medical Association; Clinical recommendations of on management of seasonal
826 and acute febrile infection [Internet]. [cited 2022 Feb 17]. Available from: [https://ima-](https://ima-india.org/ima/pdfdata/JIMA-2020/JIMA-March-2020.pdf)
827 [india.org/ima/pdfdata/JIMA-2020/JIMA-March-2020.pdf](https://ima-india.org/ima/pdfdata/JIMA-2020/JIMA-March-2020.pdf)
- 828 38. República Dominicana M de SP. Guía de manejo clínico para la infección por el virus Chikungunya
829 (chikv). 2014 May [cited 2022 Feb 17]; Available from:
830 <http://repositorio.ministeriodosalud.gob.do/handle/123456789/42>
- 831 39. Arranz Izquierdo JPE, Sanidad SE de M de F y C (semFYC) SE de MG y de F (SEMG) SE de M de
832 AP (SEMERGEN) EM de. Guía de manejo en Atención Primaria de pacientes con Dengue,
833 Chikungunya y Zika. 2006 [cited 2021 Dec 10]; Available from:
834 [http://www.msssi.gob.es/profesionales/saludPublica/ccayes/alertasActual/DocsZika/ETV3_Guia_m](http://www.msssi.gob.es/profesionales/saludPublica/ccayes/alertasActual/DocsZika/ETV3_Guia_manejo_Atencion Primaria_Marzo2016.pdf)
835 [anejo_Atencion Primaria_Marzo2016.pdf](http://www.msssi.gob.es/profesionales/saludPublica/ccayes/alertasActual/DocsZika/ETV3_Guia_manejo_Atencion Primaria_Marzo2016.pdf)
- 836 40. Guía de práctica clínica para la atención de casos de fiebre chikungunya en el Perú: Guía técnica
837 [Internet]. Ministry of Health. 2015 [cited 2021 Dec 10]. Available from:
838 [https://www.gob.pe/institucion/minsa/informes-publicaciones/320810-guia-de-practica-clinica-para-](https://www.gob.pe/institucion/minsa/informes-publicaciones/320810-guia-de-practica-clinica-para-la-atencion-de-casos-de-fiebre-chikungunya-en-el-peru-guia-tecnica)
839 [la-atencion-de-casos-de-fiebre-chikungunya-en-el-peru-guia-tecnica](https://www.gob.pe/institucion/minsa/informes-publicaciones/320810-guia-de-practica-clinica-para-la-atencion-de-casos-de-fiebre-chikungunya-en-el-peru-guia-tecnica)

- 840 41. Guidelines for Clinical Management of the Disease Produced by the Chikungunya Virus [Internet].
841 [cited 2022 Feb 17]. Available from:
842 [https://iris.paho.org/bitstream/handle/10665.2/10106/GUIA%20chikungunya%2019-03-](https://iris.paho.org/bitstream/handle/10665.2/10106/GUIA%20chikungunya%2019-03-15.pdf?sequence=1&isAllowed=y)
843 [15.pdf?sequence=1&isAllowed=y](https://iris.paho.org/bitstream/handle/10665.2/10106/GUIA%20chikungunya%2019-03-15.pdf?sequence=1&isAllowed=y)
- 844 42. WHO office for South East Asia. Guidelines on Clinical Management of Chikungunya Fever
845 [Internet]. World Health Organisation. 2008 [cited 2021 Dec 10]. Available from:
846 [https://www.who.int/publications-detail-redirect/guidelines-on-clinical-management-of-](https://www.who.int/publications-detail-redirect/guidelines-on-clinical-management-of-chikungunya-fever)
847 [chikungunya-fever](https://www.who.int/publications-detail-redirect/guidelines-on-clinical-management-of-chikungunya-fever)
- 848 43. MENJIVAR EV, FIALLOS EAE, TICAS JOR. Lineamientos técnicos para la prevención y control
849 de la fiebre Chikungunya [Internet]. MINISTERIO DE SALUD DE EL SALVADOR; 2014 [cited
850 2021 Dec 10]. Available from:
851 [https://www.salud.gob.sv/archivos/pdf/promocion_salud/material_educativo/campana_chikungunya](https://www.salud.gob.sv/archivos/pdf/promocion_salud/material_educativo/campana_chikungunya/Lineamientos_Chikungunya2014.pdf)
852 [/Lineamientos_Chikungunya2014.pdf](https://www.salud.gob.sv/archivos/pdf/promocion_salud/material_educativo/campana_chikungunya/Lineamientos_Chikungunya2014.pdf)
- 853 44. India Ministry of Health. National Guideline for Clinical Managemnt of Chikungunya [Internet].
854 2016 [cited 2021 Dec 10]. Available from:
855 <https://nvbdcp.gov.in/WriteReadData/l892s/77728737401531912419.pdf>
- 856 45. National guideline on clinical management of chikungunya fever structured online medical academy
857 [Internet]. Disease Control unit (CDC) Directorate General of Health Services (DGHS),
858 Bangladesh; 2017 [cited 2021 Dec 10]. Available from: [http://www.rcmc.com.bd/wp-](http://www.rcmc.com.bd/wp-content/uploads/2019/01/Chikungunya.pdf)
859 [content/uploads/2019/01/Chikungunya.pdf](http://www.rcmc.com.bd/wp-content/uploads/2019/01/Chikungunya.pdf)
- 860 46. Monge P, Vega JM, Sapag AM, Moreno I, Montúfar R, Khoury V, et al. Pan-American League of
861 Associations for Rheumatology-Central American, Caribbean and Andean Rheumatology
862 Association Consensus-Conference Endorsements and Recommendations on the Diagnosis and

- 863 Treatment of Chikungunya-Related Inflammatory Arthropathies in Latin America. *J Clin*
864 *Rheumatol Pract Rep Rheum Musculoskelet Dis.* 2019 Mar;25(2):101–7.
- 865 47. Organization PAH. Preparedness and Response for Chikungunya Virus: Introduction in the
866 Americas [Internet]. PAHO; 2011 [cited 2021 Dec 6]. Available from:
867 <https://iris.paho.org/handle/10665.2/4009>
- 868 48. Ecuador Ministry of Health. Preparedness and Response to the Virus Chikungunya in Ecuador
869 [Internet]. [cited 2022 Feb 17]. Available from:
870 [https://www.salud.gob.sv/archivos/pdf/promocion_salud/material_educativo/campana_chikungunya](https://www.salud.gob.sv/archivos/pdf/promocion_salud/material_educativo/campana_chikungunya/Lineamientos_Chikungunya2014.pdf)
871 [/Lineamientos_Chikungunya2014.pdf](https://www.salud.gob.sv/archivos/pdf/promocion_salud/material_educativo/campana_chikungunya/Lineamientos_Chikungunya2014.pdf)
- 872 49. Mexico Ministerio De Salud; Prevention diagnosis and treatment of chikungunya [Internet]. [cited
873 2022 Feb 17]. Available from: [https://www.gob.mx/cms/uploads/attachment/file/121729/757-](https://www.gob.mx/cms/uploads/attachment/file/121729/757-GER.compressed.compressed.compressed.pdf)
874 [GER.compressed.compressed.compressed.pdf](https://www.gob.mx/cms/uploads/attachment/file/121729/757-GER.compressed.compressed.compressed.pdf)
- 875 50. PUERTO RICO Departamento De Salud. Protocolo manejo y control de chikungunya [Internet].
876 2014. Available from: <https://www.salud.gov.pr/>
- 877 51. Marques CDL, Duarte ALBP, Ranzolin A, Dantas AT, Cavalcanti NG, Gonçalves RSG, et al.
878 Recommendations of the Brazilian Society of Rheumatology for the diagnosis and treatment of
879 chikungunya fever. Part 2 - Treatment. *Rev Bras Reumatol.* 2017;57:s438–51.
- 880 52. World Health Organisation; Tool for the diagnosis and care of patients with suspected arboviral
881 diseases [Internet]. World Health Organisation. 2017 [cited 2021 Dec 10]. Available from:
882 [https://www.who.int/publications/i/item/tool-for-the-diagnosis-and-care-of-patients-with-suspected-](https://www.who.int/publications/i/item/tool-for-the-diagnosis-and-care-of-patients-with-suspected-arboviral-diseases)
883 [arboviral-diseases](https://www.who.int/publications/i/item/tool-for-the-diagnosis-and-care-of-patients-with-suspected-arboviral-diseases)

- 884 53. Chile Ministry of Health. Technical guidance for the diagnosis and clinical management of
885 arbovirosis: dengue, chikungunya, zika and yellow fever [Internet]. MINISTERIO DE SALUD;
886 2018 [cited 2021 Dec 10]. Available from:
887 [https://corporacionbiologica.info/microbiologia/orientacion-tecnica-para-el-diagnostico-y-manejo-](https://corporacionbiologica.info/microbiologia/orientacion-tecnica-para-el-diagnostico-y-manejo-clinico-de-arbovirosis-dengue-chikungunya-zika-y-fiebre-amarilla-pdf/)
888 [clinico-de-arbovirosis-dengue-chikungunya-zika-y-fiebre-amarilla-pdf/](https://corporacionbiologica.info/microbiologia/orientacion-tecnica-para-el-diagnostico-y-manejo-clinico-de-arbovirosis-dengue-chikungunya-zika-y-fiebre-amarilla-pdf/)
- 889 54. Brito CAA de, Marques CDL, Falcão MB, Cunha RV da, Simon F, Valadares LD de A, et al.
890 Update on the treatment of musculoskeletal manifestations in chikungunya fever: a guideline. Rev
891 Soc Bras Med Trop [Internet]. 2020 Jul 31 [cited 2021 Dec 6];53. Available from:
892 <http://www.scielo.br/j/rsbmt/a/QkJVqzXqTCH8j9NFSwcT9Zh/?lang=en>
- 893 55. Salud OP de la. Guía Práctica para el Manejo Clínico de Dengue y Chikungunya; Guía para el
894 primero, segundo y tercer nivel de atención [Internet]. OPS; 2015 [cited 2021 Dec 10]. Available
895 from: <https://iris.paho.org/handle/10665.2/54558>
- 896 56. Bettis AA, Jackson ML, Yoon I-K, Breugelmans JG, Goios A, Gubler DJ, et al. The global
897 epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the
898 development and introduction of vaccines. PLoS Negl Trop Dis. 2022 Jan 12;16(1):e0010069.
- 899 57. Padmakumar B, Jayan JB, Menon RM, Krishnankutty B, Payippallil R, Nisha RS. Comparative
900 evaluation of four therapeutic regimes in chikungunya arthritis: a prospective randomized parallel-
901 group study. Indian J Rheumatol. 2009 Jul 1;4(3):94.
- 902 58. Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P, et al. Chikungunya infection:
903 an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases.
904 Medicine (Baltimore). 2007 May;86(3):123–37.
- 905 59. Parashar D, Cherian S. Antiviral Perspectives for Chikungunya Virus. BioMed Res Int.
906 2014;2014:631642.

- 907 60. Simon F, Javelle E, Oliver M, Leparc-Goffart I, Marimoutou C. Chikungunya Virus Infection. *Curr*
908 *Infect Dis Rep.* 2011;13(3):218–28.
- 909 61. Schwartz O, Albert ML. Biology and pathogenesis of chikungunya virus. *Nat Rev Microbiol.* 2010
910 Jul;8(7):491–500.
- 911 62. Renault P, Solet J-L, Sissoko D, Balleydier E, Larrieu S, Filleul L, et al. A major epidemic of
912 chikungunya virus infection on Reunion Island, France, 2005-2006. *Am J Trop Med Hyg.* 2007
913 Oct;77(4):727–31.
- 914 63. Evans-Gilbert T. Vertically transmitted chikungunya, Zika and dengue virus infections: The
915 pathogenesis from mother to fetus and the implications of co-infections and vaccine development.
916 *Int J Pediatr Adolesc Med.* 2020 Sep;7(3):107–11.
- 917 64. Charlier C, Beaudoin M-C, Couderc T, Lortholary O, Lecuit M. Arboviruses and pregnancy:
918 maternal, fetal, and neonatal effects. *Lancet Child Adolesc Health.* 2017 Oct;1(2):134–46.
- 919 65. Gérardin P. Chikungunya fever in children: From epidemiology to treatment. *Med Ther Pediatr.*
920 2012 Apr 1;15:49–56.
- 921 66. Neto ASL, Sousa GS, Nascimento OJ, Castro MC. Chikungunya-attributable deaths: A neglected
922 outcome of a neglected disease. *PLoS Negl Trop Dis.* 2019 Sep 12;13(9):e0007575.
- 923 67. Martí-Carvajal A, Ramon-Pardo P, Javelle E, Simon F, Aldighieri S, Horvath H, et al. Interventions
924 for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal
925 disorders: A systematic review. *PloS One.* 2017;12(6):e0179028.
- 926 68. Ravindran V, Alias G. Efficacy of combination DMARD therapy vs. hydroxychloroquine
927 monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open
928 label study. *Clin Rheumatol.* 2017 Jun;36(6):1335–40.

929 69. UpToDate: Evidence-based Clinical Decision Support [Internet]. [cited 2022 Feb 17]. Available
930 from: <https://www.wolterskluwer.com/en/solutions/uptodate>

931

932

933

934

935

936

937




Figure 1: PRISMA diagram



Figure 2: Chikungunya outbreaks (1999-2020) and geographic distribution of identified CMGs

The blue shading shows human Chikungunya outbreaks documented as of 1999-2020.⁵⁶ The green dots represent countries with a chikungunya clinical management guidelines (CMGs) and the numbers identified. Additionally, there were three global CMGs produced by the World Health Organisation (WHO), Medscape and Up-to-date, and three regional CMGs produced by the Pan-American Health Organisation (PAHO), WHO

South-East Asia (WHOSEA) and Pan-American League of Associations for Rheumatology-Central American Caribbean and Andean Rheumatology Association (ACCAR).

(Map adapted from Bettis, A.A and Jackson L.M et al., Plos NTD, 2022⁵⁶)




Figure 3 AGREE II domain scores

Each violin plot portrays the individual scores of the CMGs in each domain. Each dot represents a CMG proportional score per domain. The width of each curve represents the frequency of CMG scoring in each region.